You are here

immunology

Pfizer may have a lot going on in immunology, but all its drugs could be beaten by rivals: analyst

Pfizer may have a lot going on in immunology, but all its drugs could be beaten by rivals: analyst

Fierce Pharma

Flag link:

Out to revive R&D, a resurgent Sanofi pays $150M cash to partner up with a pioneering protein degradation player

Out to revive R&D, a resurgent Sanofi pays $150M cash to partner up with a pioneering protein degradation player

Endpoints

protein degradation

Flag link:

AbbVie beefs up the immunology pipeline, betting up to $865M on a PhII-ready drug — and fueling a biotech stock frenzy

AbbVie beefs up the immunology pipeline, betting up to $865M on a PhII-ready drug — and fueling a biotech stock frenzy

Endpoints

Alpine Immune Sciences

Flag link:

FDA and Immunology Experts Call for Flexible Trial Design for Pandemic Vaccines

FDA and Immunology Experts Call for Flexible Trial Design for Pandemic Vaccines

BioSpace

clinical trials

Flag link:

AbbVie's plan to replace Humira is ahead of schedule

AbbVie's plan to replace Humira is ahead of schedule

BioPharma Dive

Flag link:

AbbVie and Scripps Research Enter Research Partnership in Cancer, Immunology, Neurology and Fibrosis

AbbVie and Scripps Research Enter Research Partnership in Cancer, Immunology, Neurology and Fibrosis

BioSpace

Scripps Research Institute

Flag link:

Numero quattro: Immunology experts at deal-focused IFM line up $55.5M for the next leg of their drug exploration journey

Numero quattro: Immunology experts at deal-focused IFM line up $55.5M for the next leg of their drug exploration journey

Endpoints

IFM Therapeutics

Flag link:

Lilly counts on growing markets to boost lagging Taltz, Trulicity

Lilly counts on growing markets to boost lagging Taltz, Trulicity

Fierce Pharma

type 2 diabetes

Flag link:

AbbVie's Latest FDA Approval Is Its Most Important Immunology Win Since Humira

AbbVie's Latest FDA Approval Is Its Most Important Immunology Win Since Humira

Motley Fool

Flag link:

5 Signs of Life in Johnson & Johnson's Second-Quarter Earnings Report

5 Signs of Life in Johnson & Johnson's Second-Quarter Earnings Report

Yahoo/Motley Fool

Flag link:

Sanofi Cuts a Whopping 38 R&D Programs to Refocus on Cancer, Immunology, and Rare Diseases

Sanofi Cuts a Whopping 38 R&D Programs to Refocus on Cancer, Immunology, and Rare Diseases

BioSpace

Flag link:

J&J still sees plenty of opportunity in crowded immunology markets—starting with psoriasis

J&J still sees plenty of opportunity in crowded immunology markets—starting with psoriasis

Fierce Pharma

Flag link:

Forget Remicade -- Here's How Johnson & Johnson Plans to Grow

Forget Remicade -- Here's How Johnson & Johnson Plans to Grow

Motley Fool

Flag link:

ABBV to Focus on Advancing Late-Stage Immunology Research in 2018

ABBV to Focus on Advancing Late-Stage Immunology Research in 2018

Market Realist

Flag link:

Eli Lilly, sporting a lower tax rate, scouts smaller deals in immunology, cancer

Eli Lilly, sporting a lower tax rate, scouts smaller deals in immunology, cancer

Fierce Pharma

Flag link:

Charles River buys KWS BioTest for $20M, gaining immunology discovery capacity and a UK footprint

Charles River buys KWS BioTest for $20M, gaining immunology discovery capacity and a UK footprint

Endpoints

Charles River Laboratories

Flag link:

King cancer: The top 10 therapeutic areas in biopharma R&D

King cancer: The top 10 therapeutic areas in biopharma R&D

Endpoints

cardiovascular disease

Flag link:

U.S. prosecutors zero in on J&J marketing, targeting top immunology, hep C meds

U.S. prosecutors zero in on J&J marketing, targeting top immunology, hep C meds

Fierce Pharma

drug manufacturing

Flag link:

Immunology Among Areas to Watch as Johnson & Johnson Gears Up to Report Results

Immunology Among Areas to Watch as Johnson & Johnson Gears Up to Report Results

TheStreet.com

Flag link:

Bristol-Myers Squibb Enters Collaboration to Leverage Foundation Medicine’s Molecular Information Platform to Identify Predictive Biomarkers Across Multiple Tumor Types and Immunotherapy Agents

Bristol-Myers Squibb Enters Collaboration to Leverage Foundation Medicine’s Molecular Information Platform to Identify Predictive Biomarkers Across Multiple Tumor Types and Immunotherapy Agents

Yahoo

Bristol-Myers Squibb

Foundation Medicine

Flag link:

Pages